以非小细胞肺癌为例谈肿瘤免疫联合治疗的优化

Optimization of Combined Tumor Immunotherapy with Non-small Cell Lung Cancer asAn Example

靶向程序性细胞死亡蛋白1(PD-1)及其配体PD-L1免疫检查点抑制剂(ICIs)开创了恶性肿瘤治疗新格局。ICIs单药治疗虽然显著改善了部分患者的长期生存,但在整体人群中有效率仍然较低。因此,寻求联合治疗以进一步提高疗效成为免疫治疗发展的必然途径。各种联合模式的出现,也给医生和患者带来很多困扰。该文以非小细胞肺癌为例,聚焦免疫联合治疗中的热点问题,通过分析相关临床研究数据以及综述文献进展,提出见解,以期为免疫联合治疗优化提供思路和方向。

Immune checkpoint inhibitors(ICIs)targeting programmed cell death-1(PD-1)and its ligand(PD-L1)have transformed the traditional treatment pattern of malignant tumor.ICIs monotherapy has significantly improved long-term survival of some patients,but its efficient is low for all patient.Therefore,combined therapy is necessary for improving efficacy of immunotherapy.However,multiple patterns of combined have brought many confusions to doctors and patients.In this paper,we take non-small cell lung cancer(NSCLC)for example and focus on some hot-spot issues about ICIs-based combined therapy by analyzing clinical trial data and reviewing the progress of literature in this field.We hope to provide some ideas for the future research of optimization of ICIs-based combined therapy.